文献速递神经肿瘤

脑肿瘤纵向治疗反应自动评估:一项系统综述

Automated longitudinal treatment response assessment of brain tumors: A systematic review.
PubMed 文献 · Neuro Oncol · 2025-01-01

本系统综述遵循PRISMA指南和CLAIM清单,检索PUBMED、EMBASE和Web of Science(2010年1月至2024年11月),纳入20项使用机器学习进行成人脑肿瘤自动治疗反应评估的研究(17项回顾性、3项前瞻性),采用QUADAS-2进行质量评价;因偏倚风险高、证据水平低且数据异质性大,无法进行Meta分析,结论认为需前瞻性研究及外部数据集验证最新神经肿瘤学标准。

要点

  • 纳入20项研究(17项回顾性、3项前瞻性),评估机器学习自动纵向治疗反应评估的质量与准确性。
  • 偏倚风险高,尤其参考标准和患者选择方面适用性担忧明显,证据水平低。
  • 数据异质性大,无法进行Meta分析;需前瞻性研究及外部数据集验证最新神经肿瘤学标准。

核心结论

  • 机器学习在脑肿瘤纵向治疗反应评估方面有提升潜力。
  • 因研究偏倚和泛化性证据有限,结果解读受限。
  • 需要前瞻性研究及外部数据集验证最新神经肿瘤学标准。

研究设计与样本

  • 遵循PRISMA指南和CLAIM清单的系统综述,检索PUBMED、EMBASE和Web of Science(2010年1月至2024年11月)。
  • PROSPERO注册号CRD42024496126,聚焦使用机器学习方法的成人脑肿瘤自动治疗反应评估研究。
  • 采用QUADAS-2进行质量评价,共纳入20项研究(17项回顾性、3项前瞻性)。

主要发现

  • 提取信息包括数据集、自动反应评估流程中的相关步骤(指标测试)及参考标准。
  • 因偏倚风险高、适用性担忧(尤其参考标准和患者选择方面)及证据水平低,仅能得出有限结论。
  • 数据异质性大,不足以进行Meta分析。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 偏倚风险高,尤其参考标准和患者选择方面存在适用性担忧。
  • 证据水平低。
  • 数据异质性大,不足以进行Meta分析。
  • 泛化性证据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Longitudinal assessment of tumor burden using imaging helps to determine whether there has been a response to treatment both in trial and real-world settings. From a patient and clinical trial perspective alike, the time to develop disease progression, or progression-free survival, is an important endpoint. However, manual longitudinal response assessment is time-consuming and subject to interobserver variability. Automated response assessment techniques based on machine learning (ML) promise to enhance accuracy and reduce reliance on manual measurement. This paper evaluates the quality and performance accuracy of recently published studies. METHODS: Following PRISMA guidelines and the CLAIM checklist, we searched PUBMED, EMBASE, and Web of Science for articles (January 2010-November 2024). Our PROSPERO-registered study (CRD42024496126) focused on adult brain tumor automated treatment response assessment studies using ML methodologies. We determined the extent of development and validation of the tools and employed QUADAS-2 for study appraisal. RESULTS: Twenty (including 17 retrospective and 3 prospective) studies were included. Data extracted included information on the dataset, automated response assessment including pertinent steps within the pipeline (index tests), and reference standards. Only limited conclusions are appropriate given the high bias risk and applicability concerns (particularly regarding reference standards and patient selection), and the low-level evidence. There was insufficient homogenous data for meta-analysis. CONCLUSIONS: The study highlights the potential of ML to improve brain tumor longitudinal treatment response assessment. Interpretation is limited due to study bias and limited evidence of generalizability. Prospective studies with external datasets validating the latest neuro-oncology criteria are now required.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Shi T, Kujawa A, Linares C, et al. Automated longitudinal treatment response assessment of brain tumors: A systematic review. Neuro Oncol. 2025. PMID: 39935398. doi:10.1093/neuonc/noaf037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。